Compare Abeona Therapeutics Inc (ABEO) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Simon Property Group Inc — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Simon Property Group Inc trades at $220.33 (market cap $71.03B). The key difference: Simon Property Group Inc is far larger — about 168.6× Abeona Therapeutics Inc's market cap, and Simon Property Group Inc pays a 4.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SPG | |
|---|---|---|
Market Cap | $421.19M | $71.03B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $236.70 |
52-Week Low | $4.17 | $169.22 |
Enterprise Value | $276.10M | $99.48B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Simon Property Group (SPG) trades at $220.37, down 0.08% on the day, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings showed an EPS miss ($1.49 actual vs. $1.64 expected), though FFO beat estimates and full-year guidance was raised. The company maintains robust profitability with a net income margin of 66.57% and pays consistent dividends.
Outlook is mixed: solid operational performance and raised guidance support upside near the $226.58 consensus price target, but high debt ($24.21B) and economic sensitivity pose risks. Analyst sentiment leans neutral with 54.05% hold ratings, reflecting cautious optimism amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
